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Abstract
Objective—This study evaluated single nucleotide polymorphisms (SNPs) associated with 
progression free (PFS) and overall survival (OS) in patients with advanced stage serous EOC.
Methods—Patients enrolled in GOG-172 and 182 who provided specimens for translational 
research and consent were included. Germline DNA was evaluated with the Illumina’s 
HumanOMNI1-Quad beadchips and scanned using Illumina’s iScan optical imaging system. SNPs 
with allele frequency > 0.05 and genotyping rate > 0.98 were included. Analysis of SNPs for PFS 
and OS was done using Cox regression. Statistical significance was determined using Bonferroni 
corrected p-values with genomic control adjustment.
Results—The initial GWAS analysis included 1,124,677 markers in 396 patients. To obtain the 
final data set, quality control checks were performed and limited to serous tumors and self-
identified Caucasian race. In total 636,555 SNPs and 289 patients passed all the filters. The pre-
specified statistical level of significance was 7.855e−08. No SNPs met this criteria for PFS or OS, 
however, two SNPs were close to significance (rs10899426 p-2.144e−08) (rs6256 p-9.774e−07) for 
PFS and 2 different SNPs were identified (rs295315 p-7.536e−07; rs17693104 p-7.734e−07) which 
were close to significance for OS.
Conclusions—Using the pre-specified level of significance of 1 × 10−08, we did not identify any 
SNPs of statistical significance for OS or PFS, however several were close. The SNP’s identified 
in this GWAS study will require validation and these preliminary findings may lead to 
identification of novel pathways and biomarkers.
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1. Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecologic oncology malignancy. In 
2017 there will be approximately 22,440 newly diagnosed cases leading to 14,080 deaths in 
the United States. The overall high mortality seen in patients with EOC may be in large part 
due to 70% being diagnosed at an advanced stage [1]. Treatment of patients with advanced 
stage EOC includes a combination of platinum based chemotherapy and cytoreductive 
surgery [2,3]. A majority of patients will respond to this aggressive approach and achieve 
complete clinical remission. However, approximately 20% of patients will have platinum 
resistant disease and progress within six months of primary therapy. Patients who relapse 
within six months of completing initial treatment are classified as being primary platinum-
resistant and have a poor response to secondary treatment with response rates of 7–12% [4–
6]. These patients are often not just resistant to platinum but resistant to all cytotoxic 
therapies making them chemotherapy resistant. Historically, patients with primary platinum-
resistant disease have an estimated overall survival of 12 months from the time platinum 
resistance is identified [7]. Patients who relapse >6 months following primary platinum 
therapy are termed platinum-sensitive and have better response to secondary platinum-based 
chemotherapy with response rates of 30–60% depending on the initial platinum free interval. 
Eventually, those patients with platinum-sensitive disease will develop resistance to platinum 
therapies and can be classified as acquired platinum-resistant [4–6].
Mechanisms that underlie resistance to platinum chemotherapy are most likely multi-
factorial [8,9]. Broadly, resistance to anticancer platinum agents can be classified into two 
categories: first, platinum compounds may not reach intracellular levels needed for response 
due to inadequate delivery; and second, increased DNA damage repair mechanisms may 
lead to increased viability of tumor cells, and hence resistance [10,11]. For example, 
carboplatin works by binding to DNA and forming DNA adducts leading to intrastrand or 
interstrand cross-links which disrupt the structure of the DNA molecule, leading to steric 
changes in the helix. Alteration in the structure of the DNA molecule leads to cellular DNA 
damage recognition and repair which can result in the continued viability of the cell 
resulting in platinum-resistance [12].
Changes in front line schedule and delivery of chemotherapy, better supportive care and 
increased availability of effective agents for use at the time of recurrence have resulted in 
modest improvements in overall survival. [13] The development of novel targeted agents, 
germline BRCA screening, and emphasis on personalized therapies is starting to change the 
landscape for managing patients with ovarian cancer.
Factors that determine the aggressiveness of cancer as well as response to chemotherapy 
may be related to germ line genetic variants other than those related to homologous 
recombination, which has garnered the most interest and resulted in development of targeted 
therapies in the form of PARP inhibitors. GWAS studies performed by the international 
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ovarian cancer association consortium (OCAC) have identified 18 common SNPs associated 
with ovarian cancer risk [14]. Five additional common ovarian cancer risk SNPs were 
identified in a meta-analysis of cancer GWAS studies [15]. Studies using GWAS have also 
been performed to identify common genetic variants that impact progression free and/or 
overall survival (PFS and OS) of ovarian cancer. An OCAC study by Bolton et al. revealed 2 
SNPs at 19p13.11 (rs8170, rs2363956) that were associated with survival in an initial 
replication, but not in a second phase of replication [16]. Johnatty et al. recently published a 
large OCAC GWAS of ~2.8 million genotyped and imputed SNPs in 2900 ovarian cancer 
cases. None of the SNPs reached genome wide significance, but three of the top five loci for 
survival were associated with long non-coding RNAs [17].
This study used GWAS to identify common SNPs associated with PFS and OS among 
patients diagnosed with advanced stage epithelial ovarian cancer treated on Gynecologic 
Oncology Group (GOG) protocols 172 and 182. Identification and validation of prognostic 
and predictive SNPs for PFS and OS could provide candidate SNPs for prospective 
validation in other GOG phase III trials.
2. Patient and methods
Study population: Patients enrolled on GOG 172 and 182 who had genomic DNA available. 
DNA was extracted from WBCs recovered from whole blood using the Puregene DNA 
purification kit (GentraSystems Inc., Minneapolis, MN) or the ABI PRISM 6100 Nucleic 
Acid Prep Station (Applied Biosystems Inc., Foster City, CA). All studies received approval 
from their respective human research ethics committees, and all participants provided 
written informed consent.
2.1. GOG 172
Patients enrolled on GOG protocol 172 had stage III EOC with residual disease ≤1 cm 
following primary cytoreductive surgery (pCRS) and a GOG performance status of 0–2 and 
normal blood counts. Patients were randomly assigned to receive either 135 mg/m2 IV 
paclitaxel over 24 h day 1 followed by 75 mg/m2 of IV cisplatin day 2 or 135 mg/m2 of IV 
paclitaxel over 24 h day 1 followed by 100 mg/m2 of intraperitoneal (IP) cisplatin day 2 and 
60 mg/m2 of IP paclitaxel day 8. Six total cycles given at 21 days intervals were planned. 
The primary study endpoints were PFS and OS which were measured from the date of 
randomization. Full details of the eligibility and results are available in the published 
manuscript [18].
2.2. GOG 182
Patients enrolled on GOG protocol 182 had stage III or IV EOC with either ≤ or > 1 cm of 
residual disease following pCRS. They had GOG performance status of 0–2, normal blood 
counts and no baseline neuropathy greater than grade 1. Patients were randomized into 1 of 
5 arms each of which included 8 cycles of triplet or sequential doublet chemotherapy and 
provided a minimum of 4 cycles of carboplatin and paclitaxel IV. OS and PFS were assessed 
from the date of randomization. The primary endpoint for this study was overall survival 
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(OS). Details of the treatment arms, modifications, statistical analysis and results are 
available in the published manuscript. [19]
2.3. Single nucleotide polymorphism analysis
Illumina’s Human OMNI1-Quad beadchips (catalog #WG-311-1112) were used. The 
samples were processed through Illumina’s propriety Infinium HD Super Assay using 
Illumina’s propriety reagents. 200 ng of genomic DNA was shipped dried down and then re-
suspended, DNA was amplified with standard whole genome amplification. Samples were 
fragmented and purified with an isopropanol precipitation, re-suspended in Illumina’s 
resuspension buffer, denatured and the fragmented strands were hybridized onto 50-mer 
oligos attached to the beads on the beadchip overnight. A single-base extension was 
performed in conjunction with staining in order to determine the base at the position of 
inquiry. Beadchips were washed and coated with a sealant. The chips were finally scanned 
individually using Illumina’s iScan optical imaging system.
2.4. SNP quality control
93 individuals were classified as genetic outliers and removed. The first three calculated 
principal components were used to identify genetic outliers. This paper defined the genetic 
outliers as any sample that was plus or minus 5 standard deviations from the mean of the 
first three principal components. All subjects self- identified as Caucasian. To obtain the 
final data set, several quality control checks were performed. Filters for SNPs with call rate 
>98% and minor allele frequency >5%, sample genotyping rate >98% and Hardy Weinberg 
equilibrium threshold of 1e−08 were implemented. In total 636,555 markers and 289 patients 
passed all filters. After quality analysis and application of filters the final analysis included 
289 women, all Caucasian with epithelial ovarian cancer evaluating 636, 555 SNP’s.
2.5. Statistical analysis
SNP variables are coded as allelic dosage. All p-values reported and displayed in figures are 
adjusted by the appropriate genomic inflation factor. Survival analyses are based on the 
proportional hazards regression model, controlling the effect of population stratification by 
including three principal components in the model. Also included in the survival models 
were residual disease status (yes/no). The Bonferroni threshold for genome-wide 
significance is 7.855e−08.
3. Results
3.1. Overall survival (OS)
Demographic and tumor characteristics for the patients whose samples were included in this 
analysis are reported in Table 1. The proportional hazards regression model for each SNP 
included allelic dosage, three principal components representing population substructure and 
residual disease status. The genomic inflation factor for these analyses was 1.036 and all p-
values were correspondingly adjusted.
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The Manhattan plot for the OS p-values is shown in Fig. 1. The horizontal red line at the top 
of the plot displays the Bonferroni threshold. None of the tests exceed the cutoff, so none 
attain genome-wide statistical significance.
Supplementary Fig. 1 (supplemental figure) is a quantile-quantile plot comparing the OS test 
statistics to the values expected under the null distribution. The red line represents the 
equality of observed and expected values. This plot suggests a slight bump at moderate, non-
significant levels, which are possibly effects not discoverable due to low power.
Although none are significant, we list the top ten OS SNP effects which are candidates for 
inclusion in a higher powered study (Table 2). Ten SNPs were identified for OS; rs295315 (p 
= 7.536e−07) chromosome (Ch) 3, rs17693104 (p = 7.734e−07) Ch 10, rs868767 (p = 
1.826e−06) Ch 3, rs2050203 (p = 3.904e−06) Ch20, rs11621975 (p = 5.186e−06) Ch 14, 
rs17548007 (p = 5.288e−06) Ch 12, rs202280 (p = 6.246e−06) Ch 8, rs1564271 (p = 
8.683e−06) Ch 10, rs10899426 (p = 9.003e−06) Ch 11, rs4618572 (p = 9.182e−06) Ch 6. All 
p-values are adjusted for genomic inflation. SNP rs17693104 is located in the SDH2D4B 
gene and rs1564271 is located in the PDSS1 gene.
3.2. Progression-free survival (PFS)
The proportional hazards regression model for each SNP included allelic dosage, three 
principal components representing population substructure and residual disease status. The 
genomic inflation factor for these analyses was 1.102 and all p-values were correspondingly 
adjusted.
The Manhattan plot for the PFS p-values is shown in Fig. 2. The horizontal red line at the 
top of the plot displays the Bonferroni threshold. None of the tests exceed the cutoff, so none 
attain genome-wide statistical significance.
Supplementary Fig. 2 (supplemental figure) is a quantile-quantile plot comparing the PFS 
test statistics to the values expected under the null distribution. The red line represents the 
equality of observed and expected values. This plot suggests a slight bump at moderate, 
nonsignificant levels, which are possibly effects not discoverable due to low power.
Although none are significant, we list the top ten PFS SNP effects which are candidates for 
inclusion in a higher powered study (Table 3). The ten SNPS with largest estimated effect on 
PFS are rs10899426 (p = 2.144e−07) Ch 11, rs6256 (p = 9.774e−07) Ch 11, rs10832063 (p = 
4.534e−06) Ch 11, (rs10500780 p = 4.634e−06) Ch 11, rs281358 (p = 1.137e−05) Ch 17, 
rs17163580 (p = 1.173e−05) Ch 1, rs17011846 (p = 1.173e−05) Ch 1, rs227147 (p = 
1.381e−05), rs11782341 (p = 2.049e−05), rs7011443 (p = 2.142e−05.). All p-values are 
adjusted for genomic inflation. The genes involved include PTH, BTBD10, DISP1, UTS2, 
TUSC3, and CSMD1.
4. Discussion
This study combines prospectively collected biospecimens from two randomized phase III 
front line EOC trials in an effort to evaluate the association of germline SNPs with outcome 
for advanced EOC. These studies provide a well annotated data set that includes clinical, 
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pathological, treatment, and patient outcome data. Additionally, pathological review was 
performed by expert gynecologic pathologists to confirm ovarian cancer diagnosis. Patients 
whose pathology did not pass pathologic review were not included in this analysis. As stated 
in the methods, to avoid the genetic heterogeneity associated with ethnicity and histology, 
this analysis was limited to patients with self- reported Caucasian ethnicity. With the 
combination of excellent genomic and clinical data, this data set allows for GWAS 
evaluation of genes associated with PFS and OS in patients with advanced stage EOC.
In this GWAS study we did not identify any SNPs that met the Bonferroni threshold for 
significance for association with either OS or PFS. We did identify 10 candidate SNP’s 
associated with OS and an additional 10 candidate SNPs associated with PFS in patients 
with advanced stage serous EOC which may be interesting to reconsider in studies with 
higher power.
4.1. Overall survival
Among the 10 SNPs with potential association with overall survival, none have definitive 
association with cancer related outcomes. Two SNPs were located near genes; rs17693104 is 
located near the SH2 containing domain 4b (SH2D4b) on chromosome 10 and rs1564271 is 
located near the prenyl (decaprenyl) diphosphate synthase, subunit 1 (PDSS1). SNPs near 
SH2D4b, specifically rs6586111 and rs7915642 do have possible correlation with sensitivity 
to capecitabine across multiple cancer cell lines [20]. rs1564271 is located near PDSS1, 
defects of which cause Coenzyme Q deficiency which is associated with myalgic 
encephalomyelitis/chronic fatigue syndrome but has no association thus far with outcomes 
in malignancies [21].
Progression Free Survival: SNP rs6256 is located in Ch11 within the PTH gene and does 
have a functional association with primary hyper-parathyroid syndrome [22]. SNP rs6256 
has been evaluated as a risk factor for colon cancer with the hypothesis being that calcium 
plays a protective role and activates the tumor suppressor gene E-cadherin in human colonic 
epithelium. Alteration in calcium homeostasis either through the calcium sensing receptor 
(CaSR) or through variants in PTH might play a role in colon cancer tumorigenesis. A case 
control study (350 colon cancer cases and 510 controls) was performed in which rs6256 as 
well as rs1801725 (a variant of the CaSR gene) were evaluated. There was no difference 
between the genotype or allelic frequencies between cases and controls [23]. In a meta-
analysis of candidate SNPs affecting serum calcium found that rs10500780, a variant of 
PTH, was not significantly associated with serum calcium levels or associated sequelae such 
as bone and mineral metabolism and cardiovascular mortality [24]. While it is interesting 
that two of our most significant SNPs were associated with PTH and calcium homeostasis, 
the importance to ovarian cancer outcome and risk has not been demonstrated.
SNP rs10500780 has no known functional significance itself but is associated with BTBD10 
the protein expression of which is related to motor neuron death and amyotrophic lateral 
sclerosis [25]. SNPs rs17011846 and rs17163580 are associated with the DISP1 gene and 
have implicated to be involved in the Hedgehog signaling pathway in cancer. Studies in non-
small cell lung cancer tumor microarray data demonstrate a negative association between 
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PFS and OS and overexpression of DISP1 [26]. This particular SNP has no known clinical 
association currently.
SNP rs11782441 is in the CSMD1 gene which is a candidate tumor suppressor gene. Loss of 
CSMD1 expression is associated with high tumor grade and poor survival in invasive ductal 
breast carcinoma [27] and SNP rs227147 is associated with the gene UTS2 (Urotensin II) 
the function of which is felt to contribute to angiogenesis and certain polymorphisms (not 
this one) have been associated with breast cancer risk [28].
Finally, SNP rs7011443 is found within the TUSC3 gene which is another candidate tumor 
suppressor gene. Epigenetic silencing of this gene has been associated with poor prognosis 
and is an independent negative prognostic biomarker for PFS and OS in ovarian cancer. The 
molecular role of TUSC3 in ovarian cancer is not known [29].
Recently, the OCAC reported on a genome wide analysis which included patients with EOC 
from 13 OCAC studies. Patients included in The Cancer Genome Atlas (TCGA) were used 
as a validation set. Included patients underwent a cytoreductive surgery and were of 
European ancestry. 2901 patients made up the main data set with a subset of 1098 who were 
known to have received ≥4 cycles of paclitaxel and carboplatin chemotherapy. This study 
evaluated over 2.8 million SNPs for association with EOC outcome and identified SNPs at 5 
loci with significance for overall and progression free survival. These SNPs included 
rs6674079, rs7950311 rs4910232, rs2549714, rs3795247. Three of these SNPs (rs6674079, 
rs4910232 and rs2549714) were found to be located in long coding RNAs. This is 
significant in that long coding RNAs are transcripts that have been associated with cancer 
progression through their impact on regulatory functions including epigenetic control, 
regulation of chromatin structure, regulation of angiogenesis and others [17]. We attempted 
to evaluate these 5 SNPs in our dataset. 3 of the SNPs were available and none were 
significant for PFS or OS. These included PFS (rs6674079; rs7950311 and rs4910232) and 
OS (rs6674079; rs7950311 and rs4910232) analysis.
In collaboration with the OCAC investigators, the top 10 SNPs identified in the GOG dataset 
were evaluated in a large dataset with 6160 patients with data on OS and 5596 patients with 
data on PFS. When the dataset was restricted to those patient who received at least 4 cycles 
of “standard chemotherapy” this number was 2620 patients. Only Euro-pean samples as 
determined by principal component analysis were included [30]. Samples underwent 
analysis via OncoArray which is a custom designed Illumina array consisting of 533,000 
variants. 260,660 of these variants comprise the GWAS analysis for this OCAC study [31]. 
The top 10 SNPs for PFS and OS were evaluated in this data set both in all histologies as 
well as a high grade serous only subset and none were validated for either PFS or OS [32].
In this GWAS study we did not identify any SNPs that met the Bonferroni threshold for 
significance in their association with PFS and OS but we did identified 10 candidate SNP’s 
for both PFS and OS which might be interesting on further evaluation in higher powered 
studies. It is interesting in that the SNP rs10899426 was found on both lists as possibly 
associated with PFS and OS and this is worthy of further evaluation in future studies.
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Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ygyno.
2017.08.024.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• GWAS may identity single nucleotide polymorphisms (SNPs) associated with 
survival.
• This GWAS study failed to identify SNPs associated with PFS or OS.
• Larger GWAS analyses may prove more insightful.
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Fig. 1. 
Manhattan plot for overall survival. The horizontal red line displays the Bonferroni threshold 
which was not crossed by any polymorphism indicating lack of statistical significance.
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Fig. 2. 
Manhattan plot for progression free survival. The horizontal red line displays the Bonferroni 
threshold which was not crossed by any polymorphism indicating lack of statistical 
significance.
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Table 1
Demographics table.
Total GOG 172 GOG 182
(N = 289) (N = 147) (N = 142)
Age: median (range) 57.79 (30,87) 57.22 (34,83) 59.13 (30,87)
Stage of disease
 III 268 147 121
 IV 21 0 21
Size of residual disease
 Microscopic 92 56 36
 Gross 197 91 106
 Not assessed
Histologic features
 Serous 220 110 (50%) 110(50%)
 Endometrioid 19 8(42%) 11(58%)
 Mixed 18 13(72%) 5(28%)
 Clear Cell 17 10(59%) 7(41%)
 Other 15 6(40%) 9(60%)
Grade
 1 20 9(45%) 11(55%)
 2 107 60(56%) 47(44%)
 3 157 76(48%) 81(52%)
 NA 5 2(40%) 3(60%)
Performance Status
 0 133 64(48%) 69(52%)
 1 136 70(51%) 66(49%)
 2 20 13(65%) 7(35%)
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